Literature DB >> 28912121

Cortical Bone Stem Cell Therapy Preserves Cardiac Structure and Function After Myocardial Infarction.

Thomas E Sharp1, Giana J Schena1, Alexander R Hobby1, Timothy Starosta1, Remus M Berretta1, Markus Wallner1, Giulia Borghetti1, Polina Gross1, Daohai Yu1, Jaslyn Johnson1, Eric Feldsott1, Danielle M Trappanese1, Amir Toib1, Joseph E Rabinowitz1, Jon C George1, Hajime Kubo1, Sadia Mohsin1, Steven R Houser2.   

Abstract

RATIONALE: Cortical bone stem cells (CBSCs) have been shown to reduce ventricular remodeling and improve cardiac function in a murine myocardial infarction (MI) model. These effects were superior to other stem cell types that have been used in recent early-stage clinical trials. However, CBSC efficacy has not been tested in a preclinical large animal model using approaches that could be applied to patients.
OBJECTIVE: To determine whether post-MI transendocardial injection of allogeneic CBSCs reduces pathological structural and functional remodeling and prevents the development of heart failure in a swine MI model. METHODS AND
RESULTS: Female Göttingen swine underwent left anterior descending coronary artery occlusion, followed by reperfusion (ischemia-reperfusion MI). Animals received, in a randomized, blinded manner, 1:1 ratio, CBSCs (n=9; 2×107 cells total) or placebo (vehicle; n=9) through NOGA-guided transendocardial injections. 5-ethynyl-2'deoxyuridine (EdU)-a thymidine analog-containing minipumps were inserted at the time of MI induction. At 72 hours (n=8), initial injury and cell retention were assessed. At 3 months post-MI, cardiac structure and function were evaluated by serial echocardiography and terminal invasive hemodynamics. CBSCs were present in the MI border zone and proliferating at 72 hours post-MI but had no effect on initial cardiac injury or structure. At 3 months, CBSC-treated hearts had significantly reduced scar size, smaller myocytes, and increased myocyte nuclear density. Noninvasive echocardiographic measurements showed that left ventricular volumes and ejection fraction were significantly more preserved in CBSC-treated hearts, and invasive hemodynamic measurements documented improved cardiac structure and functional reserve. The number of EdU+ cardiac myocytes was increased in CBSC- versus vehicle- treated animals.
CONCLUSIONS: CBSC administration into the MI border zone reduces pathological cardiac structural and functional remodeling and improves left ventricular functional reserve. These effects reduce those processes that can lead to heart failure with reduced ejection fraction.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  cell therapy; hemodynamics; myocardial infarction; stem cells; swine; ventricular remodeling

Mesh:

Year:  2017        PMID: 28912121      PMCID: PMC5681384          DOI: 10.1161/CIRCRESAHA.117.311174

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  56 in total

1.  Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.

Authors:  Susan Stewart; Gayle L Winters; Michael C Fishbein; Henry D Tazelaar; Jon Kobashigawa; Jacki Abrams; Claus B Andersen; Annalisa Angelini; Gerald J Berry; Margaret M Burke; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Charles C Marboe; Bruce McManus; Elaine F Reed; Nancy L Reinsmoen; E Rene Rodriguez; Alan G Rose; Marlene Rose; Nicole Suciu-Focia; Adriana Zeevi; Margaret E Billingham
Journal:  J Heart Lung Transplant       Date:  2005-06-20       Impact factor: 10.247

2.  Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Bojan Vrtovec; Gregor Poglajen; Luka Lezaic; Matjaz Sever; Aljaz Socan; Dragoslav Domanovic; Peter Cernelc; Guillermo Torre-Amione; François Haddad; Joseph C Wu
Journal:  Circulation       Date:  2013-09-10       Impact factor: 29.690

3.  Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring.

Authors:  Tony Stanton; Rodel Leano; Thomas H Marwick
Journal:  Circ Cardiovasc Imaging       Date:  2009-07-21       Impact factor: 7.792

4.  Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation.

Authors:  Konstantinos E Hatzistergos; Henry Quevedo; Behzad N Oskouei; Qinghua Hu; Gary S Feigenbaum; Irene S Margitich; Ramesh Mazhari; Andrew J Boyle; Juan P Zambrano; Jose E Rodriguez; Raul Dulce; Pradip M Pattany; David Valdes; Concepcion Revilla; Alan W Heldman; Ian McNiece; Joshua M Hare
Journal:  Circ Res       Date:  2010-07-29       Impact factor: 17.367

5.  Human CD34+ cells in experimental myocardial infarction: long-term survival, sustained functional improvement, and mechanism of action.

Authors:  Jingxiong Wang; Sui Zhang; Brian Rabinovich; Luc Bidaut; Suren Soghomonyan; Mian M Alauddin; James A Bankson; Elizabeth Shpall; James T Willerson; Juri G Gelovani; Edward T H Yeh
Journal:  Circ Res       Date:  2010-05-06       Impact factor: 17.367

6.  Number of nuclei in isolated myocardial cells of pigs.

Authors:  W Gräbner; P Pfitzer
Journal:  Virchows Arch B Cell Pathol       Date:  1974

Review 7.  Why Is Infarct Expansion Such an Elusive Therapeutic Target?

Authors:  William J Richardson; Jeffrey W Holmes
Journal:  J Cardiovasc Transl Res       Date:  2015-09-21       Impact factor: 4.132

8.  Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial.

Authors:  Joshua M Hare; Darcy L DiFede; Angela C Rieger; Victoria Florea; Ana M Landin; Jill El-Khorazaty; Aisha Khan; Muzammil Mushtaq; Maureen H Lowery; John J Byrnes; Robert C Hendel; Mauricio G Cohen; Carlos E Alfonso; Krystalenia Valasaki; Marietsy V Pujol; Samuel Golpanian; Eduard Ghersin; Joel E Fishman; Pradip Pattany; Samirah A Gomes; Cindy Delgado; Roberto Miki; Fouad Abuzeid; Mayra Vidro-Casiano; Courtney Premer; Audrey Medina; Valeria Porras; Konstantinos E Hatzistergos; Erica Anderson; Adam Mendizabal; Raul Mitrani; Alan W Heldman
Journal:  J Am Coll Cardiol       Date:  2016-11-14       Impact factor: 24.094

9.  Echocardiographic speckle-tracking based strain imaging for rapid cardiovascular phenotyping in mice.

Authors:  Michael Bauer; Susan Cheng; Mohit Jain; Soeun Ngoy; Catherine Theodoropoulos; Anna Trujillo; Fen-Chiung Lin; Ronglih Liao
Journal:  Circ Res       Date:  2011-03-03       Impact factor: 17.367

10.  A characterization and targeting of the infarct border zone in a swine model of myocardial infarction.

Authors:  Jason M Duran; Sharven Taghavi; Remus M Berretta; Catherine A Makarewich; Thomas Sharp Iii; Tim Starosta; Foram Udeshi; Jon C George; Hajime Kubo; Steven R Houser
Journal:  Clin Transl Sci       Date:  2012-06-26       Impact factor: 4.689

View more
  26 in total

Review 1.  Potential clinical benefits of cell therapy in coronary heart disease: an update.

Authors:  Vincenzo Grimaldi; Alberto Zullo; Francesco Donatelli; Francesco Paolo Mancini; Francesco Cacciatore; Claudio Napoli
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

2.  Cortical bone-derived stem cell therapy reduces apoptosis after myocardial infarction.

Authors:  Alexander R H Hobby; Thomas E Sharp; Remus M Berretta; Giulia Borghetti; Eric Feldsott; Sadia Mohsin; Steven R Houser
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-23       Impact factor: 4.733

3.  Nonocclusive multivessel intracoronary infusion of allogeneic cardiosphere-derived cells early after reperfusion prevents remote zone myocyte loss and improves global left ventricular function in swine with myocardial infarction.

Authors:  Gen Suzuki; Brian R Weil; Rebeccah F Young; James A Fallavollita; John M Canty
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-24       Impact factor: 4.733

4.  Cortical Bone Stem Cells Administered at Reperfusion Attenuate Remote Zone Myocyte Remodeling.

Authors:  John M Canty; Brian R Weil
Journal:  Circ Res       Date:  2017-11-10       Impact factor: 17.367

Review 5.  New Paradigms in Cell Therapy: Repeated Dosing, Intravenous Delivery, Immunomodulatory Actions, and New Cell Types.

Authors:  Marcin Wysoczynski; Abdur Khan; Roberto Bolli
Journal:  Circ Res       Date:  2018-07-06       Impact factor: 17.367

6.  Cortical bone stem cell-derived exosomes' therapeutic effect on myocardial ischemia-reperfusion and cardiac remodeling.

Authors:  Giana J Schena; Emma K Murray; Alycia N Hildebrand; Alaina L Headrick; Yijun Yang; Keith A Koch; Hajime Kubo; Deborah Eaton; Jaslyn Johnson; Remus Berretta; Sadia Mohsin; Raj Kishore; Timothy A McKinsey; John W Elrod; Steven R Houser
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-10-08       Impact factor: 4.733

7.  Cortical bone stem cells modify cardiac inflammation after myocardial infarction by inducing a novel macrophage phenotype.

Authors:  Alexander R H Hobby; Remus M Berretta; Deborah M Eaton; Hajime Kubo; Eric Feldsott; Yijun Yang; Alaina L Headrick; Keith A Koch; Marcello Rubino; Justin Kurian; Mohsin Khan; Yinfei Tan; Sadia Mohsin; Stefania Gallucci; Timothy A McKinsey; Steven R Houser
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-08-20       Impact factor: 5.125

8.  An off-the-shelf artificial cardiac patch improves cardiac repair after myocardial infarction in rats and pigs.

Authors:  Ke Huang; Emily W Ozpinar; Teng Su; Junnan Tang; Deliang Shen; Li Qiao; Shiqi Hu; Zhenhua Li; Hongxia Liang; Kyle Mathews; Valery Scharf; Donald O Freytes; Ke Cheng
Journal:  Sci Transl Med       Date:  2020-04-08       Impact factor: 17.956

9.  A realistic appraisal of the use of embryonic stem cell-based therapies for cardiac repair.

Authors:  Marcin Wysoczynski; Roberto Bolli
Journal:  Eur Heart J       Date:  2020-07-01       Impact factor: 29.983

10.  RNA stability protein ILF3 mediates cytokine-induced angiogenesis.

Authors:  Christine N Vrakas; Allison B Herman; Mitali Ray; Sheri E Kelemen; Rosario Scalia; Michael V Autieri
Journal:  FASEB J       Date:  2018-11-01       Impact factor: 5.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.